Regeneron (REGN) Tops Q1 EPS by 35c, Updates FY Guidance
Tweet
Share
E-mail
Get Alerts REGN Hot Sheet
EPS Growth %: -15.8%
Financial Fact:
Loss from operations: 362.8M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Regeneron (NASDAQ: REGN) reported Q1 EPS of $4.67, $0.35 better than the analyst estimate of $4.32. Revenue for the quarter came in at $1.51 billion versus the consensus estimate of $1.51 billion.
2018 Financial Guidance(3)
The Company's updated full year 2018 financial guidance consists of the following components:
Sanofi collaboration revenue: Sanofi reimbursement of Regeneron commercialization-related expenses | $450 million–$485 million (previously $450 million–$500 million) |
Non-GAAP unreimbursed R&D(2)(4) | $1.230 billion–$1.310 billion (previously $1.230 billion–$1.330 billion) |
Non-GAAP SG&A(2)(4) | $1.325 billion–$1.395 billion (previously $1.350 billion–$1.450 billion) |
Effective tax rate | 15%–18% (previously 15%–19%) |
Capital expenditures | $420 million–$480 million (previously $420 million–$500 million) |
For earnings history and earnings-related data on Regeneron (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
